Current Report Filing (8-k)
March 03 2020 - 6:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February
25, 2020
Medicine Man Technologies, Inc.
(Exact Name of Registrant
as Specified in Its Charter)
Nevada
|
001-36868
|
46-5289499
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
4880 Havana Street, Suite 201
Denver, Colorado
|
|
80239
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
(303) 371-0387
|
(Registrant’s Telephone Number, Including Area Code)
|
|
|
|
Not Applicable
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchange On Which Registered
|
Not applicable
|
|
Not applicable
|
|
Not applicable
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
In connection with
the previously announced resignation of Andy Williams from the positions of President and member on the Board of Directors of Medicine
Man Technologies, Inc. (the “Company”), on February 25, 2020, the Company entered into a Severance Agreement and Release
(the “Severance Agreement”) with Mr. Williams.
The Severance Agreements
provides that as severance and in consideration of a customary release against the Company and other customary covenants, Mr. Williams
will receive (i) continued salary in the amount of $300,000, half of which is to be paid within ten days of the execution of the
Severance Agreement, and the remaining half is to be paid in 26 equal disbursements in accordance with the Company’s regular
payroll periods, (ii) bonus payment in the amount of $25,000, (iii) one year family health care coverage, (iv) stock options to
purchase 350,000 shares of the Company’s common stock, which may be exercised on a cashless basis, and (v) stock options
to purchase 15,000 shares of the Company’s common stock, which may be exercised on a cashless basis.
The full text of the
Severance Agreement is filed herewith as Exhibit 10.1 and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
(d)
|
Exhibits
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MEDICINE MAN TECHNOLOGIES, INC.
|
|
|
|
By:
|
/s/ Justin Dye
|
Date: March 2, 2020
|
|
Justin Dye
Chief Executive Officer
|
Medicine Man Technologies (CE) (USOTC:SHWZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicine Man Technologies (CE) (USOTC:SHWZ)
Historical Stock Chart
From Sep 2023 to Sep 2024